The proliferation of the middle class within developing nations has resulted in a substantial rise in Type 2 diabetes
(PRWEB) February 15, 2013
The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease.
The purpose of this report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market.
This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Detailed tables and charts with sales forecasts and market share data are also included.
Companies Mentioned include: LifeScan, Roche Diagnostics Corporation, Bayer, Abbott (MediSense), Agamatrix, Inc., Arkray, Inc. Bionime Corporation, BioSense Medical Devices, Diabetic Supply of Suncoast, Prodigy Diabetes Care, LLC, Entra Health Systems and many more.
For more information, please visit http://www.researchandmarkets.com/research/tvkvw7/world_glucose
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716